Circulating High Mobility Group Box-1 Does Not Predict Pulmonary Arterial Hypertension in Children with Congenital Heart Disease: A Prospective Cohort Study.

Autor: Caracci B; Department of Anesthesiology and Pain Medicine, The Hospital for Sick Children and The University of Toronto, Ontario, Canada., Pehora C; Department of Anesthesiology and Pain Medicine, The Hospital for Sick Children and The University of Toronto, Ontario, Canada., Benson L; Department of Cardiology, The Hospital for Sick Children, Toronto, Ontario, Canada., Steinberg BE; Department of Anesthesiology and Pain Medicine, The Hospital for Sick Children and The University of Toronto, Ontario, Canada., Goldenberg NM; Department of Anesthesiology and Pain Medicine, The Hospital for Sick Children and The University of Toronto, Ontario, Canada., Taylor K; Department of Anesthesiology and Pain Medicine, The Hospital for Sick Children and The University of Toronto, Ontario, Canada. Electronic address: Katherine.taylor@sickkids.ca.
Jazyk: angličtina
Zdroj: Journal of cardiothoracic and vascular anesthesia [J Cardiothorac Vasc Anesth] 2024 Oct; Vol. 38 (10), pp. 2356-2361. Date of Electronic Publication: 2024 Jul 11.
DOI: 10.1053/j.jvca.2024.07.020
Abstrakt: Objectives: Pulmonary arterial hypertension (PAH) is a devastating complication of pediatric congenital heart disease (CHD). A recent study has identified the protein high mobility group box-1 (HMGB1) as a diagnostic tool in adults with CHD-associated PAH. HMGB1 levels in adults with CHD-associated PAH correlated with mean pulmonary artery pressure and pulmonary vascular resistance, and HGMB1 levels fell in response to sildenafil therapy. We wanted to assess if HGMB1 was a biomarker of pediatric CHD-PAH.
Design: Prospective cohort study.
Setting: Quaternary pediatric academic hospital PARTICIPANTS: Children ≤18 years with CHD with and without known pulmonary hypertension. Controls were children undergoing dental or urologic surgery with no known heart disease.
Interventions: Pulmonary hemodynamics, echocardiographic assessment, and biomarker measurement. Controls had biomarker measurement only.
Measurements and Main Results: Patients with CHD-PAH had mean pulmonary vascular resistance index of 10 Wood units/m 2 . Neither HGMB1 nor N-terminal pro-brain-type natriuretic peptide levels were significantly different between the groups. Neither marker correlated with pulmonary hypertension.
Conclusions: Unlike in adults, HGMB1 is not a biomarker of PAH in pediatric CHD. Further work will continue to explore for biomarkers for this high-risk population.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: